1. Scrip

Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market

 
• By Emily Hayes

Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.

car racing in tunnel

Pfizer Inc./Merck KGAA are working fast to move their combination of the PD-L1 inhibitor Bavencio (avelumab) and Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib) into the first-line advanced kidney cancer market, based on interim Phase III progression-free survival data.

The companies announced positive top-line results Sept. 11 for the combination of Bavencio with Pfizer's Inlyta vs. the firm’s older...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.